tbuckley/cabot-search huggingface dataset:
STEM-25. HDAC1 IS ESSENTIAL FOR GLIOMA STEM CELL SURVIVAL
Authors: Costanza Lo Cascio, James McNamara, Ernesto Luna Melendez, Shwetal Mehta
Journal: Neuro-Oncology (2019)

Abstract OLIG2 is a central nervous system-specific transcription factor that is expressed in almost all diffuse gliomas. It is also one of the key core transcription factors that can reprogram differentiated glioma cells to highly tumorigenic glioma stem-like cells (GSCs). We have previously shown that expression of OLIG2 is critical for glioma growth both in a genetically relevant mouse model as well as in patient-derived xenograft models. Our work suggests that a small molecule inhibitor of OLIG2 could serve as a highly targeted therapy for high-grade glioma; however, transcription factors are generally very difficult to target because their interactions with DNA and co-regulatory proteins involve large and complex surface area contacts. Our laboratory has shown that OLIG2 functions are regulated through interactions with distinct co-regulator proteins in normal neural stem cells. However, there are currently no reports on interactors that promote the proto-oncogenic functions of OLIG2 in malignant glioma. In this study, we employed two independent proteomics screens identify tumor-specific, druggable OLIG2 co-regulators as possible surrogate targets to suppress OLIG2 function in glioma. These screens led to the identification of a novel OLIG2 partner protein: Histone Deacetylase 1 (HDAC1). We confirmed that this interaction occurs in both murine and human glioma models. Although HDACs are ubiquitously expressed and are known to be functionally redundant, we show that ablation of HDAC1 alone significantly decreases the stemness and proliferation capacity of patient-derived GSCs in a p53-dependent manner, while having a minimal impact on normal human neural stem cells and astrocytes. Furthermore, we demonstrate that knockdown of HDAC1, in combination with ionizing radiation treatment, significantly alters the growth pattern of intracranial tumors in vivo. We demonstrate that HDAC1 function is critical for GSC growth and provide a strong rationale for targeting the OLIG2-HDAC1 interaction in malignant glioma.
Physical Medicine and Rehabilitation
Authors: Charles D. Bonner
Journal: New England Journal of Medicine (1964)

WAR, dedication and education are the three forces that have created the concept of physical medicine and rehabilitation as it is known today. A formal history of the development of the concept of rehabilitation is not as yet available. Descriptions of care and assistance rendered to disabled persons date back many centuries. The Old Testament book of Leviticus records that Moses and Aaron received detailed instructions pertaining to the management of impaired persons. Evidence of rituals and the rules applicable to disabled people in ancient eastern and primitive societies can be found that resemble some of the things done for . . .
Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia
Authors: Elizabeth Rogers, Maho Hibino, Rebecca Garcia Hunt, Leslie Renee Ellis, Rupali Bhave, Dianna S. Howard, Susan Lyerly, Sarah Dralle, Megan Manuel, Timothy S. Pardee, Bayard L Powell
Journal: Blood (2019)
Sexual Life, Fertility and Ovarian Function in Women after Allogeneic Hematopoietic Stem Cell Transplant
Authors: Forgeard Nathalie, Matthieu Jestin, Dominique Vexiau, Florian Chevillon, Régis Peffault de Latour, Marie Robin, Flore Sicre de Fontbrune, Alienor Xhaard, David Michonneau, Nicolas Boissel, Catherine Poirot, Nathalie Dhedin
Journal: Blood (2019)
Treatment of Gonorrhoea
Authors: T. E. Osmond
Journal: BMJ (1952)

Late Consulting Venereologist to the ArmyThe treatment of acute gonococcal urethritis may be summed up briefly in the words " 200,000 units of peni- cillin."But there is more in it than that, for it is axio- matic throughout medicine that it is just as important to treat the patient as it is to treat the disease; more- over, gonorrhoea is almost invariably contracted from another person, and it cannot be too strongly stressed that it is the duty of every medical man to do his utmost to trace the original source of infection and bring him or her to treatment.This is necessary in the interest not only of the original person infected but also of the public health; in this connexion it is to be noted that it is an offence for any person other than a registered medical practitioner to treat venereal disease.
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Authors: Rajat Bannerji, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H Advani, Jeffrey A. Barnes, Stephen M Ansell, Susan M. O'Brien, Julio Chavez, Johannes Duell, Kevin A. David, Peter Martin, Robin M. Joyce, Robert Charnas, Srikanth R. Ambati, Lieve Adriaens, Melanie Ufkin, Min Zhu, Jingjin Li, Peter Gasparini, Anfal Ibrahim, Vladimir Jankovic, Nathalie Fiaschi, Olulanu Aina, Wen Zhang, Raquel P. Deering, Sara Hamon, Gavin Thurston, Andrew J. Murphy, David M. Weinreich, George D. Yancopoulos, Israel Lowy, David Sternberg, Max S. Topp
Journal: Blood (2019)
Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL
Authors: Paulina Richter-Pechanska, Joachim B. Kunz, Jana Hof, Martin Zimmermann, Tobias Rausch, Obul Reddy Bandapalli, Elena Orlova, Greta Scapinello, Judit Sagi, Martin Stanulla, Martin Schrappe, Renate Kirschner-Schwabe, Cornelia Eckert, Vladimir Benes, Jan O. Korbel, Martina U. Muckenthaler, Andreas E Kulozik
Journal: Blood (2016)
Dissolving Microneedles: Rational Design of Rapidly Separating Dissolving Microneedles for Precise Drug Delivery by Balancing the Mechanical Performance and Disintegration Rate (Adv. Healthcare Mater. 21/2019)
Authors: Ailin Hou, Guilan Quan, Beibei Yang, Chao Lu, Minglong Chen, Dan Yang, Lili Wang, Hu Liu, Xin Pan, Chuanbin Wu
Journal: Advanced Healthcare Materials (2019)

In article number 1900898 by Xin Pan, Chuanbin Wu, and co-workers, a rapidly separating dissolving microneedles (RSDMNs) system is constructed to achieve controlled and precise drug delivery. The polymer-sugar complex is used to constitute the separating part with high disintegration rate as well as sufficient mechanical performance. After administration, the blank separating part rapidly disintegrates and detaches from the base and embeds the drug-concentrated tips into the skin. Both the ex vivo and in vivo results confirm the superiority of RSDMNs as compared with traditional dissolving microneedles.
Beneficial Effects of Sunlight May Account for the Correlation Between Serum Vitamin D Levels and Cardiovascular Health
Authors: Richard B. Weller
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Authors: Maria Luisa Lozano, Maria Eva Mingot-Castellano, María Perera, Isidro Jarque, Rosa Maria Campos, Tomás José González-López, Gonzalo Carreño Gomez-Tarragona, Nuria Bermejo, Maria Fernanda Lopez Fernandez, Aurora de Andrés, David Valcarcel, Felipe Casado, Teresa Álvarez Roman, María Isabel Orts, Silvana Novelli, Jose Ramon González-Porras, Estefanía Bolaños, Manuel Rodríguez López, Elisa Orna, Vicente Vicente Garcia
Journal: Blood (2019)
ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS
Authors: Karisa Schreck, Fang-Chi Hsu, Adam Berrington, Bobbie J Henry-Barron, Lindsay Blair, Adam Hartman, Eric Kossoff, Linda Easter, Mary Self, Chris Whitlow, Peter Barker, Mackenzie Cervenka, Jaishri O Blakeley, Roy Strowd
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Exploiting metabolic vulnerabilities via ketosis is a promising approach for gliomas. The modified Atkins diet is a ketogenic diet therapy efficacious in adults with refractory epilepsy. We evaluated the feasibility, pharmacokinetics/pharmacodynamics(PK/PD), and cerebral activity of this dietary intervention intended to induce ketosis. METHODS 25 patients with biopsy-confirmed WHO Grade 2–4 astrocytoma with stable disease after adjuvant chemotherapy were enrolled in an 8-week GLioma Atkins-based Diet (GLAD). GLAD consisted of 2 ‘intermittent fasting’ days(IF; calories &lt; 20% of recommended daily allowance) interleaved between 5 modified-Atkins diet days(MAD; carbohydrates &lt; 20 gm/day) each week. The primary outcome was dietary compliance. Secondary outcomes were PK assessed by urine ketones post-FAST and post-MAD, PD assessed by serum insulin and IGF-1, and cerebral activity measured by MR spectroscopy at baseline and week 8. RESULTS Grade 2(n=2;8%), Grade 3(n=11;44%) and GBMs(n=12;48%) were enrolled. While only 48% of participants satisfied pre-defined compliance criteria, overall compliance with MAD(80%) was higher than IF(72%). Weight loss was observed (-4.8 + 2.2kg,p&lt; 0.0001) consisting primarily of decreased fat mass (-2.5 + 3.1%,p&lt; 0.0001), with increased lean body mass (2.4 + 3.2%,p&lt; 0.0001), stable nutritional status (phase angle, -0.26 + 0.94%,p=0.22), and normalization of BMI. Urine acetoacetate significantly increased with 55% achieving moderate ketosis at week 8 (p=0.0005). Serum insulin and IGF-1 significantly decreased indicating systemic dietary response and were associated with higher ketones post-IF, but not post-MAD. MRS demonstrated cerebral activity with increased ketones in lesional (0.06±0.03- &gt;0.27±0.06i.u,p=0.005) and contralateral brain at week 8 (0.041±0.01- &gt;0.16±0.04i.u.,p=0.004). Higher cerebral acetone correlated with higher urine ketones (r &gt;0.75,p&lt; 0.02) and lower fasting glucose (r &gt;-0.74,p&lt; 0.05). CONCLUSIONS The GLAD diet was challenging to maintain but demonstrated quantifiable biologic effects systemically and intratumorally. MAD was more feasible than IF, but changes in PD markers correlated most strongly with IF. The role of ketogenic diet therapy for preventing glioma growth remains uncertain.
First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)
Authors: David I Marks, Amy A. Kirkwood, Clare J Rowntree, Melanie Aguiar, Katharine E Bailey, Brendan Beaton, Laura Clifton-Hadley, Emma Lawrie, SooWah Lee, Andrew K McMillan, Anthony V. Moorman, Rachel J. Mitchell, Pip Patrick, Tobias F Menne, Paul Smith, Bela Wrench, Krisztina Zuborne Alapi, Adele K. Fielding
Journal: Blood (2019)
PDCT-07. EARLY RESULTS OF THE EMULATE THERAPEUTICS HÆLO™ SYSTEM IN PEDIATRIC BRAIN TUMORS
Authors: Andrew Chang, Sharon Gardner, Jerry Jaboin, Sarah Leary, Rebecca Loret De Mola, Edward McClay, Donna Morgan Murray, Kellie Nazemi, Atmaram Pai Panandiker, Michael Salacz, Stacie Stapleton, Santosh Kesari, Michael Prados
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The EMulate Therapeutics Hælo system is an investigational non-sterile, non-invasive, non-thermal, non-ionizing, portable, home-use medical device that uses a specific, localized ultra-low radio frequency energy (ulRFE®) cognate for the treatment of pediatric brain tumors. METHODS Sixteen patients with brain tumors consisting of diffuse midline glioma/diffuse intrinsic pontine glioma (DMG/DIPG, n=14), recurrent medulloblastoma (n=1), or anaplastic astrocytoma (n=1) – were treated with the Hælo under FDA’s single-patient compassionate use pathway, as protocol deviations in a glioblastoma trial, or under TGA’s Special Access Scheme. Baseline information and on-treatment safety and exposure data were collected. RESULTS Patients ranged in age from 4 to 28 years (median = 8 years) and were diagnosed 91 – 1399 days (median = 397 days) prior to treatment with the Hælo system. Patients were treated for 2 – 52 weeks (median = 15 weeks), with 4 patients still alive (all with a diagnosis of DMG/DIPG), and 3 still on treatment (ranging 18 – 52 weeks). Two out of the 16 patients reported mild-moderate adverse events - one patient reported nausea, fatigue, and excessive sleepiness, and one patient reported vomiting. No device-related serious adverse events were reported. Other adverse events reported were generally associated with progressive disease. Unsolicited, anecdotal reports from some parents/caregivers noted improvements in mobility, speech, and visual acuity while on treatment. CONCLUSIONS The Hælo system appears to be safe and feasible for the treatment of pediatric brain tumors. Given that therapy is delivered non-invasively and no device-related serious adverse events were reported, further prospective study of the investigational device is warranted.
Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns
Authors: Muharrem Muftuoglu, Vivian Ruvolo, Yuki Nishida, Po Yee Mak, Peter P. Ruvolo, Bing Z Carter, Michael Andreeff
Journal: Blood (2019)
Niche Transfer of Small Non-Coding RNAs Regulates Hematopoietic Response to Stress
Authors: Youmna Kfoury, Fei Ji, Michael Mazzola, David B Sykes, Anselmo Anthony, Yasutoshi Akiyama, Allison Scherer, Francois Mercier, Nicolas Severe, Borja Saez, Jefferson Seidl, Ani Papazian, Thomas Brouse, Michael K Mansour, Pavel Ivanov, Ruslan I Sadreyev, David T. Scadden
Journal: Blood (2019)
Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2
Authors: Daniela Steinbrecher, Felix Seyfried, Eugen Tausch, Johannes Bloehdorn, Billy Michael Chelliah Jebaraj, Klaus-Michael Debatin, Lüder Hinrich Meyer, Hartmut Döhner, Stephan Stilgenbauer, Christof Schneider
Journal: Blood (2019)
TMIC-05. GLIOBLASTOMA CONTAINS TOPOLOGICALLY DISTINCT PROLIFERATIVE AND METABOLICALLY DEFINED SUBPOPULATIONS OF NESTIN AND GLUT1-POSITIVE CELLS
Authors: Michael Prosniak, Lawrence Kenyon, D Craig Hooper, David Andrews
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM), the most aggressive primary brain malignancy, consists of diverse cell subpopulations expressing a variety of cell lineage markers. Improvements in GBM therapy and survival require a deeper knowledge of the shifting subpopulations of tumorigenic cells within typical GBMs and their relative vulnerabilities. GBM development is associated with the appearance of highly proliferative tumor cells that lead to a hypoxic, metabolically reprogrammed, immunosuppressive microenvironment that favors tumor progression. In addition, GBM contains self-renewing, tumorigenic cancer stem cells (CSC) that contribute to tumor initiation and therapeutic resistance. Using a combined multicolor immunofluorescent and Hematoxylin and Eosin (H&amp;E) staining approach with archival formalin-fixed, paraffin embedded tissue from primary, recurrent, and autopsy glioblastoma specimens, we have investigated the complex topology of the GBM microenvironment with particular focus on the association and distribution of several important functional and metabolic markers. High-resolution tissue image analysis permitted precise colocalization and quantification of four biomarkers (Ki-67, GLUT1, Nestin, Hif-1a) of the entire specimen image and at the single cell level. Our results demonstrate discrete subpopulations with specific regional localization with respect to blood vessels and to each other. In particular, highly proliferative Nestin-positive cells are preferentially located near blood vessels. These cells do not express GLUT1 and are Hif-1a positive. In contrast, GLUT1-positive cells are negative for Nestin, demonstrate low proliferation, and are preferentially located at the zones of pseudopalisading necrosis, furthest from blood vessels. In addition, GLUT1-positive cells show reduced Hif-1a expression compared to Nestin-positive cells. Our novel approach provides a means to identify, characterize, and monitor the changing nature of GBM before and after various treatment modalities with the ultimate aim of revealing selective vulnerabilities in order to retard or cure this neoplasm.
Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms
Authors: Terra Lasho, Alexander Tischer, Guadalupe Belen Antelo, Animesh Pardanani, Christy Finke, Giacomo Coltro, Wilson I Gonsalves, Ayalew Tefferi, Abhishek A Mangaonkar, Naseema Gangat, Mrinal M Patnaik
Journal: Blood (2019)
Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome
Authors: Robert F. Sidonio, Dunlei Cheng, Christine Guelcher, Janna M. Journeycake, Susan U Lattimore, Clifford Takemoto, Michael D. Tarantino, Crystal Watson, Ellis J. Neufeld, Carol Fedor
Journal: Blood (2019)
Clinical Implications of Copy Number Variant Detection from Panel-Based Next-Generation Sequencing Data in Myelodysplastic Syndrome
Authors: Je-Hwan Lee, Yoo-Jin Kim, Seung-Hyun Jung, Eun-Hye Hur, Eun-Ji Choi, Kyoo Hyung Lee, Seon-Hee Yim, Hye-Jung Kim, Yong-Rim Kwon, Young-Woo Jeon, Sug Hyung Lee, Yeun-Jun Chung
Journal: Blood (2019)
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions
Authors: Noriaki Yoshida, Kay Shigemori, Nicholas Donaldson, Christopher Trevisani, Nicolas A. Cordero, Kristen E. Stevenson, Xia Bu, Fumiko Arakawa, Mai Takeuchi, Koichi Ohshima, Akinori Yoda, Samuel Y. Ng, David M. Weinstock
Journal: Blood (2020)
Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma
Authors: Francis K. Buadi, Martha Q. Lacy, Angela Dispenzieri, Gabriela Perez, Morie A. Gertz, Prashant Kapoor, Suzanne R. Hayman, David Dingli, Ronald S. Go, Amie Fonder, Yi L. Hwa, Miriam A. Hobbs, Wilson I Gonsalves, Dania Kaehlyn Helgeson, Taxiarchis Kourelis, Betsy Laplant, Stephen J Russell, Eli Muchtar, Rahma M Warsame, S. Vincent Rajkumar, Robert A. Kyle, Shaji K. Kumar
Journal: Blood (2019)
Injury frequency and characteristics (location, type, cause and severity) differed significantly among athletics (‘track and field’) disciplines during 14 international championships (2007–2018): implications for medical service planning
Authors: Pascal Edouard, Laurent Navarro, Pedro Branco, Vincent Gremeaux, Toomas Timpka, Astrid Junge
Journal: British Journal of Sports Medicine (2019)

To analyse differences between athletic disciplines in the frequency and characteristics of injuries during international athletics championships.Study design, injury definition and data collection procedures were similar during the 14 international championships (2007-2018). National medical teams and local organising committee physicians reported all newly incurred injuries daily on a standardised injury report form. Results were presented as number of injuries and number of injuries per 1000 registered athletes, separately for male and female athletes, and for each discipline.From a total of 8925 male and 7614 female registered athletes, 928 injuries were reported in male and 597 in female athletes. The discipline accounting for the highest proportion of injuries was sprints, for both men (24%) and women (26%). The number of injuries per 1000 registered athletes varied between disciplines for men and women: highest in combined events for male athletes (235 (95% CI 189 to 281)) and female athletes (212 (95% CI 166 to 257)), and lowest for male throwers (47 (95% CI 35 to 59)) and female throwers (32 (95% CI 21 to 43)) and for female race walkers (42 (95% CI 19 to 66)). Injury characteristics varied significantly between disciplines for location, type, cause and severity in male and female athletes. Thigh muscle injuries were the main diagnoses in the disciplines sprints, hurdles, jumps, combined events and race walking, lower leg muscle injuries in marathon running, lower leg skin injury in middle and long distance running, and trunk muscle and lower leg muscle injuries in throws.Injury characteristics differed substantially between disciplines during international athletics championships. Strategies for medical service provision (eg, staff, facilities) during athletics championships should be discipline specific and be prepared for targeting the main injuries in each discipline.
The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants
Authors: Michal Ariela Raz, Jon E. Arnason, Osnat Bairey, Lev Shvidel, Ariel Aviv, Sharon Ben Baruch, Chava Perry, Nadav Sarid, David Varon, Ilya Kirgner, Yair Herishanu, Irit Avivi
Journal: Blood (2019)
FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim
Authors: Ayako Nogami, Daisuke Watanabe, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohda, Osamu Miura
Journal: Blood (2019)